Modulation of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on executive functions in humans

Animal studies point to an implication of the endocannabinoid system on executive functions. In humans, several studies have suggested an association between acute or chronic use of exogenous cannabinoids (Δ9-tetrahydrocannabinol) and executive impairments. However, to date, no published reports est...

ver descrição completa

Detalhes bibliográficos
Autores: Fagundo, Ana Beatriz, Torre Fornell, Rafael de la, Jiménez-Murcia, Susana, Agüera, Zaida, Pastor, Antoni, Casanueva, Felipe F., Granero, Roser, Baños Rivera, Rosa María, Botella Arbona, Cristina, Del Pino Gutiérrez, Amparo, Fernández-Real Lemos, José Manuel, Fernández García, José C., Frühbeck, Gema, Gómez Ambrosi, Javier, Menchón Magriñá, José Manuel, Moragrega, Inés, Rodríguez, Roser, Tárrega, Salomé, Tinahones, Francisco J., Fernández Aranda, Fernando
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2013
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositório:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/65652
Acesso em linha:https://hdl.handle.net/2445/65652
Access Level:Acceso aberto
Palavra-chave:Cànnabis
Cognició
Presa de decisions
Endocrinologia
Cannabis
Cognition
Decision making
Endocrinology
id ES_fa73093dfa3adfafd5703e8978b18cde
oai_identifier_str oai:recercat.cat:2445/65652
network_acronym_str ES
network_name_str España
repository_id_str
spelling Modulation of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on executive functions in humansFagundo, Ana BeatrizTorre Fornell, Rafael de laJiménez-Murcia, SusanaAgüera, ZaidaPastor, AntoniCasanueva, Felipe F.Granero, RoserBaños Rivera, Rosa MaríaBotella Arbona, CristinaDel Pino Gutiérrez, AmparoFernández-Real Lemos, José ManuelFernández García, José C.Frühbeck, GemaGómez Ambrosi, JavierMenchón Magriñá, José ManuelMoragrega, InésRodríguez, RoserTárrega, SaloméTinahones, Francisco J.Fernández Aranda, FernandoCànnabisCognicióPresa de decisionsEndocrinologiaCannabisCognitionDecision makingEndocrinologyAnimal studies point to an implication of the endocannabinoid system on executive functions. In humans, several studies have suggested an association between acute or chronic use of exogenous cannabinoids (Δ9-tetrahydrocannabinol) and executive impairments. However, to date, no published reports establish the relationship between endocannabinoids, as biomarkers of the cannabinoid neurotransmission system, and executive functioning in humans. The aim of the present study was to explore the association between circulating levels of plasma endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) and executive functions (decision making, response inhibition and cognitive flexibility) in healthy subjects. One hundred and fifty seven subjects were included and assessed with the Wisconsin Card Sorting Test; Stroop Color and Word Test; and Iowa Gambling Task. All participants were female, aged between 18 and 60 years and spoke Spanish as their first language. Results showed a negative correlation between 2-AG and cognitive flexibility performance (r = −.37; p<.05). A positive correlation was found between AEA concentrations and both cognitive flexibility (r = .59; p<.05) and decision making performance (r = .23; P<.05). There was no significant correlation between either 2-AG (r = −.17) or AEA (r = −.08) concentrations and inhibition response. These results show, in humans, a relevant modulation of the endocannabinoid system on prefrontal-dependent cognitive functioning. The present study might have significant implications for the underlying executive alterations described in some psychiatric disorders currently associated with endocannabinoids deregulation (namely drug abuse/dependence, depression, obesity and eating disorders). Understanding the neurobiology of their dysexecutive profile might certainly contribute to the development of new treatments and pharmacological approaches.Public Library of Science (PLoS)2015201520132015info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion7 p.application/pdfhttps://hdl.handle.net/2445/65652Articles publicats en revistes (Ciències Clíniques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0066387PLoS One, 2013, vol. 8, num. 6, p. 1-7http://dx.doi.org/10.1371/journal.pone.0066387cc-by (c) Fagundo, Anna B. et al., 2013http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:recercat.cat:2445/656522026-05-29T05:05:01Z
dc.title.none.fl_str_mv Modulation of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on executive functions in humans
title Modulation of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on executive functions in humans
spellingShingle Modulation of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on executive functions in humans
Fagundo, Ana Beatriz
Cànnabis
Cognició
Presa de decisions
Endocrinologia
Cannabis
Cognition
Decision making
Endocrinology
title_short Modulation of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on executive functions in humans
title_full Modulation of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on executive functions in humans
title_fullStr Modulation of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on executive functions in humans
title_full_unstemmed Modulation of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on executive functions in humans
title_sort Modulation of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on executive functions in humans
dc.creator.none.fl_str_mv Fagundo, Ana Beatriz
Torre Fornell, Rafael de la
Jiménez-Murcia, Susana
Agüera, Zaida
Pastor, Antoni
Casanueva, Felipe F.
Granero, Roser
Baños Rivera, Rosa María
Botella Arbona, Cristina
Del Pino Gutiérrez, Amparo
Fernández-Real Lemos, José Manuel
Fernández García, José C.
Frühbeck, Gema
Gómez Ambrosi, Javier
Menchón Magriñá, José Manuel
Moragrega, Inés
Rodríguez, Roser
Tárrega, Salomé
Tinahones, Francisco J.
Fernández Aranda, Fernando
author Fagundo, Ana Beatriz
author_facet Fagundo, Ana Beatriz
Torre Fornell, Rafael de la
Jiménez-Murcia, Susana
Agüera, Zaida
Pastor, Antoni
Casanueva, Felipe F.
Granero, Roser
Baños Rivera, Rosa María
Botella Arbona, Cristina
Del Pino Gutiérrez, Amparo
Fernández-Real Lemos, José Manuel
Fernández García, José C.
Frühbeck, Gema
Gómez Ambrosi, Javier
Menchón Magriñá, José Manuel
Moragrega, Inés
Rodríguez, Roser
Tárrega, Salomé
Tinahones, Francisco J.
Fernández Aranda, Fernando
author_role author
author2 Torre Fornell, Rafael de la
Jiménez-Murcia, Susana
Agüera, Zaida
Pastor, Antoni
Casanueva, Felipe F.
Granero, Roser
Baños Rivera, Rosa María
Botella Arbona, Cristina
Del Pino Gutiérrez, Amparo
Fernández-Real Lemos, José Manuel
Fernández García, José C.
Frühbeck, Gema
Gómez Ambrosi, Javier
Menchón Magriñá, José Manuel
Moragrega, Inés
Rodríguez, Roser
Tárrega, Salomé
Tinahones, Francisco J.
Fernández Aranda, Fernando
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cànnabis
Cognició
Presa de decisions
Endocrinologia
Cannabis
Cognition
Decision making
Endocrinology
topic Cànnabis
Cognició
Presa de decisions
Endocrinologia
Cannabis
Cognition
Decision making
Endocrinology
description Animal studies point to an implication of the endocannabinoid system on executive functions. In humans, several studies have suggested an association between acute or chronic use of exogenous cannabinoids (Δ9-tetrahydrocannabinol) and executive impairments. However, to date, no published reports establish the relationship between endocannabinoids, as biomarkers of the cannabinoid neurotransmission system, and executive functioning in humans. The aim of the present study was to explore the association between circulating levels of plasma endocannabinoids N-arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) and executive functions (decision making, response inhibition and cognitive flexibility) in healthy subjects. One hundred and fifty seven subjects were included and assessed with the Wisconsin Card Sorting Test; Stroop Color and Word Test; and Iowa Gambling Task. All participants were female, aged between 18 and 60 years and spoke Spanish as their first language. Results showed a negative correlation between 2-AG and cognitive flexibility performance (r = −.37; p<.05). A positive correlation was found between AEA concentrations and both cognitive flexibility (r = .59; p<.05) and decision making performance (r = .23; P<.05). There was no significant correlation between either 2-AG (r = −.17) or AEA (r = −.08) concentrations and inhibition response. These results show, in humans, a relevant modulation of the endocannabinoid system on prefrontal-dependent cognitive functioning. The present study might have significant implications for the underlying executive alterations described in some psychiatric disorders currently associated with endocannabinoids deregulation (namely drug abuse/dependence, depression, obesity and eating disorders). Understanding the neurobiology of their dysexecutive profile might certainly contribute to the development of new treatments and pharmacological approaches.
publishDate 2013
dc.date.none.fl_str_mv 2013
2015
2015
2015
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/65652
url https://hdl.handle.net/2445/65652
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0066387
PLoS One, 2013, vol. 8, num. 6, p. 1-7
http://dx.doi.org/10.1371/journal.pone.0066387
dc.rights.none.fl_str_mv cc-by (c) Fagundo, Anna B. et al., 2013
http://creativecommons.org/licenses/by/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by (c) Fagundo, Anna B. et al., 2013
http://creativecommons.org/licenses/by/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 7 p.
application/pdf
dc.publisher.none.fl_str_mv Public Library of Science (PLoS)
publisher.none.fl_str_mv Public Library of Science (PLoS)
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425212398764032
score 15,812429